Bent Høie waxa uu helay warbixinta guddiga khubarada ee tallaallada AstraZeneca iyo Johnson & Johnson
Isniintii, May 10, wasiirka caafimaadka iyo daryeelka, Bent Høie, ayaa gudoomay guddiga khabiirada warbixintii ku saabsan isticmaalka tallaalka fayraska ee Norway. Warbixintu waxay soo jeedinaysaa in tallaallada AstraZeneca iyo Johnson & Johnson aan lagu isticmaalin barnaamijka tallaalka Covid-19 ee Norway. Guddigu waxa ay ku talinayaan in tallaalo laga dhigo meel ka baxsan barnaamijka, laakiin waxay u qaybsan yihiin shuruudaha isticmaalka noocaas ah lagu saleynayo.
Dawladdu waxay doonaysay qiimayn ballaadhan oo ay ku jirto waayo-aragnimada tallaalladan laga keenay waddamo kale
Dawladdu waxay doonaysay qiimayn ballaadhan oo ay ku jirto waayo-aragnimada tallaalladan laga keenay waddamo kale iyo micnaha dib-u-dhigista tallaalku marka la eego culaysyada saaran dadka iyo bulshada guud ahaan. Sidaa darteed, waxaa la aasaasay guddi khubaro ah si ay u daraaseeyaan cawaaqibka ka dhalan kara isticmaalka ama la'aanta tallaalka vector sida AstraZeneca iyo Johnson & Johnson.
Guddiga khabiiradu waxay sameeyeen qiimayn khatar ah oo dhamaystiran oo ku saabsan isticmaalka tallaalada ay ku jiraan fayraska
– Komishanku wuxuu qabtay shaqo aad u wanaagsan oo wanaagsan muddo gaaban gudaheed. Dawladdu hadda waxay si taxadir leh dib u eegis ugu samayn doontaa warbixinta oo waxay u isticmaali doontaa gundhigga go'aankeeda, iyadoo ay la socoto talada Machadka Qaranka ee Caafimaadka Dadweynaha. Tani waxay lagama maarmaan u tahay in meel looga soo wada jeesto isticmaalka tallaaladan, ayuu yidhi Høie markii uu helay warbixinta.
Guddiga khubarada, oo uu madax u yahay Lars Vorland, ayaa sameeyay qiimeyn ballaaran oo ku saabsan khatarta isticmaalka tallaalada fayraska, labadaba heer shakhsi iyo mid bulsho. Guddigu wuxuu ka kooban yahay xubno heer qaran ah iyo kuwo caalami ah waxaana lagu qiimeeyay, waxyaabo kale, xogta caalamiga ah ee waxyeelada iyo halista.
Talaalka dadwaynuhu waa arin muhiim u ah in dib loo furo bulshada Norway.
Isticmaalka tallaalka AstraZeneca ayaa si ku-meel-gaar ah loo joojiyay 11-kii Maarso ee sanadkan markii la ogaaday waxyeellooyin dhif ah laakiin aad u daran. Bishii Abriil, Machadka Qaranka ee Caafimaadka Dadweynaha ayaa ku taliyay in tallaalkan laga saaro barnaamijka tallaalka khatarta ah waxyeellooyin naadir ah oo aad halis u ah. NIPH waxay ku talisay tan iyada oo la eegayo xaaladda Norway, oo heerka caabuqa uu aad u hooseeyo.
Waxaan helnaa sahayda sii kordheysa ee tallaalka Pfizer-BioNTech, a cilmi-baaristu waxay muujisayin aan helno ilaalin aad u wanaagsan saddex toddobaad ka dib
– Dhawr ayaa dhawaan soo muuqday war wanaagsan oo ku saabsan Talaalo. Waxaan helnaa sahayda sii kordheysa ee tallaalka Pfizer-BioNTech, cilmi-baaristuna waxay muujisay inaan helno ilaalin aad u wanaagsan saddex toddobaad uun kaddib markii qiyaasta koowaad ee tallaalka. Taasi waa sababta aan u kordhinay muddada u dhaxaysa qiyaasta koowaad iyo labaad ee tallaalka si aan dad badan u tallaalno si degdeg ah. Dhammaan arrimahan ayaa ka dhigaya wax aan wanaagsanayn in meesha laga saaro isticmaalka tallaalka fayraska, ayuu yidhi Høie.
Bent Høie waxa uu helay warbixinta guddiga khubarada ee tallaallada AstraZeneca iyo Johnson & Johnson
Guddigu wuxuu soo gabagabeeyey in tallaalada fayraska fayraska ee la qaatay guud ahaan ay yihiin tallaalo wax ku ool ah oo ka dhan ah COVID-19
Guddi khubaro ah ayaa sameeyay qiimayno anshax iyo sharci, falanqayn dhaqan-dhaqaale, iyo qiimaynta caafimaadka iyo saamaynta bulshada. Guddigu wuxuu soo gabagabeeyey in tallaalada fayraska fayraska ee la qaatay guud ahaan ay yihiin tallaalo wax ku ool ah oo ka dhan ah COVID-19. Talada ah in aan iyaga lagu darin barnaamijka tallaalka waxay ka dhalanaysaa xaaladda caabuqa ee Norway. Guddigu waxa ay rumaysan yihiin in aanay weli suurtogal ahayn in la go'aamiyo cidda khatarta sii kordheysa ee waxyeellooyin halis ah sida xinjirowga dhiigga iyo tirada platelet oo hooseeya, ka hor ama ka dib tallaalka. Sidoo kale hadda ma jirto daaweyn wax ku ool ah oo loogu talagalay saameynaha daran.
Warbixinta guddiga khabiirada ee AstraZeneca iyo Johnson & Johnson. Waxay ku nuuxnuuxsadeen in dadku ay si fiican u qiimeyn karaan khatarta, xaaladdooda iyo baahida loo qabo in laftigooda la tallaalo
Guddigu wuxuu u qaybsan yahay shuruudaha loo isticmaali karo isticmaalka ikhtiyaarka ah ee tallaallada AstraZeneca iyo Johnson & Johnson ee ka baxsan barnaamijka tallaalka. Badankoodu waxay aaminsan yihiin in xaaladda caabuqa ee hadda ka jirta Noorway ay muujinayso in bixinta tallaalladan si ikhtiyaari ah ay tahay mid si gaar ah loo caddeeyey. Tiro yar oo khubarada ah ayaa aaminsan in tallaallada AstraZeneca iyo Johnson & Johnson lagu bixin karo warqad dhakhtar qoray kuwa doonaya. Waxay ku nuuxnuuxsadeen in dadku ay si fiican u qiimeyn karaan khatarta, xaaladdooda iyo baahida loo qabo in la tallaalo dhowr toddobaad ka hor.
